Profil Financier
Thomas Struengmann & family occupe actuellement le rang #312 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $11.3 B (+$260 sur 24h).
Thomas Struengmann and twin brother Andreas were early backers of German firm BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.
The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.
The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
After obtaining a business degree from the University of Augsburg, Thomas worked as a marketing manager for Schering-Plough.
Like his brother, an identical twin, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.